MEDI-528, now recognized as enokiizumab , represents a innovative medication targeting the IGF1R, a crucial protein involved in various skin more info conditions . Early trial findings suggest considerable potential for the control of significant atopic dermatitis , particularly in those who have failed existing treatments . This monoclonal antibod